collection
MENU ▼
Read by QxMD icon Read
search

Renal Anemia

shared collection
123 papers 100 to 500 followers
By Isabel Acosta-Ochoa Nephrology senior staff. Valladolid. Spain
https://www.readbyqxmd.com/read/29967232/anemia-and-iron-deficiency-in-heart-failure-current-concepts-and-emerging-therapies
#1
REVIEW
Inder S Anand, Pankaj Gupta
Anemia and iron deficiency are important and common comorbidities that often coexist in patients with heart failure. Both conditions, together or independently, are associated with poor clinical status and worse outcomes. Whether anemia and iron deficiency are just markers of heart failure severity or whether they mediate heart failure progression and outcomes and therefore should be treated is not entirely clear. Treatment of anemia in patients with heart failure with erythropoiesis-stimulating agents has been evaluated intensively during the past several years...
July 3, 2018: Circulation
https://www.readbyqxmd.com/read/29982259/iron-homeostasis-pathways-as-therapeutic-targets-in-acute-kidney-injury
#2
Sundararaman Swaminathan
BACKGROUND: Iron is critical for fundamental biologic functions such as cell division and mitochondrial electron transport. However, by the virtue of its ability to donate electrons, iron is probably the most effective oxidant in biologic systems. SUMMARY: To avoid damage from iron-mediated oxidative injury or ferroptosis, multiple defense mechanisms exist including iron binding proteins and robust glutathione-dependent intracellular pathways. Hepcidin, through its ability to sequester iron within macrophages and induce H-ferritin, serves as an endogenous protective molecule against ferroptosis...
July 6, 2018: Nephron
https://www.readbyqxmd.com/read/29958932/misdistribution-of-iron-and-oxidative-stress-in-chronic-kidney-disease
#3
Takeshi Nakanishi, Takahiro Kuragano, Masayoshi Nanami, Yasuyuki Nagasawa, Yukiko Hasuike
Chronic kidney disease (CKD) patients have an extremely high risk of developing cardiovascular diseases (CVD) compared to the general population. Systemic inflammation associated with oxidative stress could be an important determinant of morbidity and mortality associated with CVD. We suspected that dysregulation of iron metabolism should be considered in these patients. Anemia is prevalent in CKD patients and is often treated with erythropoiesis-stimulating agents (ESAs) and iron. In addition, iron administration sometimes causes iron overdose...
June 26, 2018: Free Radical Biology & Medicine
https://www.readbyqxmd.com/read/29956370/when-should-iron-supplementation-in-dialysis-patients-be-avoided-minimized-or-withdrawn
#4
EDITORIAL
Guy Rostoker
Parenteral iron is used to restore the body's iron pool before and during erythropoiesis-stimulating agent (ESA) therapy; together these agents form the backbone of anemia management in end-stage renal disease (ESRD) patients undergoing hemodialysis. ESRD patients receiving chronic intravenous iron products, which exceed their blood loss are exposed to an increased risk of positive iron balance. Measurement of the liver iron concentration (LIC) reflects total body iron stores in patients with secondary hemosiderosis and genetic hemochromatosis...
June 28, 2018: Seminars in Dialysis
https://www.readbyqxmd.com/read/29939850/emerging-therapeutic-options-for-management-of-anaemia-in-with-patients-with-chronic-kidney-disease
#5
Sehrish Ali, Natasha Dave, Sankar D Navaneethan
No abstract text is available yet for this article.
June 22, 2018: Current Opinion in Nephrology and Hypertension
https://www.readbyqxmd.com/read/29930419/-impact-of-anemia-and-chronic-kidney-disease-on-the-risk-of-cardiovascular-disease-and-all-cause-mortality-among-diabetic-patients
#6
C Yang, J W Wang, Y Z Yang, K H Bai, B X Gao, M H Zhao, L X Zhang, S L Wu, F Wang
OBJECTIVE: To explore the association between anemia and cardiovascular disease and all-cause mortality among diabetic patients, and whether the association is modified by the presence of chronic kidney disease (CKD). METHODS: Physical examination data of 8 563 patients with diabetes who met the inclusion and exclusion criteria between 2010 and 2011 were collected, based on the prospective cohort data of Kailuan study. The deadline of the follow-up was December 31, 2015, and the endpoints comprised all-cause mortality and cardiovascular disease...
June 18, 2018: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/29933406/anemia-modifies-the-prognostic-value-of-glycated-hemoglobin-in-patients-with-diabetic-chronic-kidney-disease
#7
I-Ching Kuo, Hugo You-Hsien Lin, Sheng-Wen Niu, Jia-Jung Lee, Yi-Wen Chiu, Chi-Chih Hung, Shang-Jyh Hwang, Hung-Chun Chen
A common complication of chronic kidney disease (CKD), anemia can influence glycated hemoglobin (HbA1c) levels. In diabetic patients, anemia occurs earlier and with higher severity over the course of CKD stages. To elucidate the effect of hemoglobin (Hb) on the predictive value of HbA1c, we enrolled 1558 diabetic patients with stages 3-4 CKD, categorized according to baseline Hb and HbA1c quartiles. Linear regression revealed that higher HbA1c correlated significantly with higher Hb in the Hb < 10 g/dL group (β = 0...
2018: PloS One
https://www.readbyqxmd.com/read/29921869/tubular-iron-deposition-and-iron-handling-proteins-in-human-healthy-kidney-and-chronic-kidney-disease
#8
Sanne van Raaij, Rachel van Swelm, Karlijn Bouman, Maaike Cliteur, Marius van den Heuvel, Jeanne Pertijs, Dominic Patel, Paul Bass, Harry van Goor, Robert Unwin, Surjit Kaila Srai, Dorine Swinkels
Iron is suggested to play a detrimental role in the progression of chronic kidney disease (CKD). The kidney recycles iron back into the circulation. However, the localization of proteins relevant for physiological tubular iron handling and their potential role in CKD remain unclear. We examined associations between iron deposition, expression of iron handling proteins and tubular injury in kidney biopsies from CKD patients and healthy controls using immunohistochemistry. Iron was deposited in proximal (PT) and distal tubules (DT) in 33% of CKD biopsies, predominantly in pathologies with glomerular dysfunction, but absent in controls...
June 19, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29923765/physiological-functions-of-ferroportin-in-the-regulation-of-renal-iron-recycling-and-ischemic-acute-kidney-injury
#9
Xueqiao Wang, Xiaoqing Zheng, Juanlian Zhang, Shifeng Zhao, Zhigang Wang, Fudi Wang, Wenjun Shang, Jonathan Barasch, Andong Qiu
Renal iron recycling preserves the filtered iron from urinary excretion. However, it remains debated whether ferroportin (FPN), the solely known iron exporter, is functionally involved in renal iron recycling, and whether renal iron recycling is required for systemic iron homeostasis. We deleted FPN in the whole nephrons using a Nestin-Cre and in the distal nephrons and collecting ducts using a Ksp-Cre, and investigated its impacts on renal iron recycling and systemic iron homeostasis. FPN deletion by Nestin-Cre but not by Ksp-Cre caused excess iron retention and increased ferritin heavy chain (FTH1) specifically in the proximal tubules, and resulted in the reduction of serum and hepatic iron...
June 20, 2018: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/29909605/anemia-in-conventional-hemodialysis-finding-the-optimal-treatment-balance
#10
Takeshi Hasegawa, Fumihiko Koiwa, Tadao Akizawa
Renal anemia is a serious and common complication in hemodialysis (HD) patients. The introduction of erythropoiesis-stimulating agents (ESAs) has dramatically improved hemoglobin levels and outcomes. Several interventional studies reported that excessive correction of anemia and the massive use of ESA can trigger cardiovascular disease (CVD), and consequently may worsen the prognosis of patients undergoing HD. Therefore, it has been widely recognized that large doses of ESA should be used with caution. An effective use of iron preparations is required to yield the optimal effect of ESA...
June 17, 2018: Seminars in Dialysis
https://www.readbyqxmd.com/read/29909502/increased-ngal-level-associated-with-iron-store-in-chronic-kidney-disease-with-anemia
#11
Daijun Xiang, Xiuying Wang, Peipei Liu, Yuling Pan, Qian Zhang, Xiuping Chi, Ying Jing, Xinxin Duan, Qiaozhen Wei, Jianan Wang, Mianyang Li, Chengbin Wang
An iron scarcity often occurs in chronic kidney disease (CKD). Neutrophil gelatinase-associated lipocalin (NGAL), a biomarker of acute kidney injury, is associated with iron metabolism. The present study determined the association between serum NGAL and iron status in chronic kidney disease with anemia. A total of 154 adult CKD patients were divided into anemia and without anemia groups. The anemia groups were further subdivided into two groups based on the presence or absence of iron deficiency, defined as a transferrin saturation (TSAT) < 20%...
June 16, 2018: Clinical and Experimental Medicine
https://www.readbyqxmd.com/read/29905580/iron-therapy-for-managing-anaemia-in-chronic-kidney-disease
#12
Iain C Macdougall
PURPOSE OF REVIEW: Iron deficiency is a major contributory cause to the development of anaemia in chronic kidney disease (CKD), and thus, iron replacement therapy plays a critical role in the management of this condition. The two main routes for administering iron are oral and intravenous, and there have been a number of new publications relevant to both routes of administration. RECENT FINDINGS: Recent developments on the topic of iron management in CKD include the introduction of new oral iron preparations, as well as two recent meta-analyses on iron therapy in CKD (one on oral versus intravenous iron, and one on high- versus low-dose intravenous iron in haemodialysis patients)...
June 13, 2018: Current Opinion in Nephrology and Hypertension
https://www.readbyqxmd.com/read/29659573/whole-body-iron-transport-and-metabolism-mechanistic-multi-scale-model-to-improve-treatment-of-anemia-in-chronic-kidney-disease
#13
Joydeep Sarkar, Alka A Potdar, Gerald M Saidel
Iron plays vital roles in the human body including enzymatic processes, oxygen-transport via hemoglobin and immune response. Iron metabolism is characterized by ~95% recycling and minor replenishment through diet. Anemia of chronic kidney disease (CKD) is characterized by a lack of synthesis of erythropoietin leading to reduced red blood cell (RBC) formation and aberrant iron recycling. Treatment of CKD anemia aims to normalize RBC count and serum hemoglobin. Clinically, the various fluxes of iron transport and accumulation are not measured so that changes during disease (e...
April 2018: PLoS Computational Biology
https://www.readbyqxmd.com/read/29900001/transfusion-management-of-incident-dialysis-patients-in-canada-a-prospective-observational-study
#14
Aminu K Bello, Christine M Ribic, Serge H Cournoyer, Mercedeh Kiaii, Martine LeBlanc, Melanie Poulin-Costello, David N Churchill, Norman Muirhead
Background: Several studies have demonstrated harm associated with using erythropoiesis-stimulating agents (ESA) to achieve higher hemoglobin (Hb) levels. Subsequently, more conservative use of ESAs has changed anemia therapy in patients with chronic renal failure. Objective: The objectives were to identify transfusion rates in hemodialysis (HD) patients during the first year of therapy, to identify factors associated with the probability of transfusion, describe reasons for the transfusions, and identify the Hb values associated with each transfusion...
2018: Canadian Journal of Kidney Health and Disease
https://www.readbyqxmd.com/read/29890958/anemia-and-mortality-in-patients-with-nondialysis-dependent-chronic-kidney-disease
#15
Heide A Stirnadel-Farrant, Jiacong Luo, Lata Kler, Borut Cizman, Delyth Jones, Steven M Brunelli, Alexander R Cobitz
BACKGROUND: A combination of safety concerns and labeling changes impacted use of erythropoiesis-stimulating agents (ESAs) in renal anemia. Data regarding contemporary utilization in pre-dialysis chronic kidney disease (CKD) are lacking. METHODS: Electronic healthcare records and medical claims data of pre-dialysis CKD patients were aggregated from a large US managed care provider (2011-13). ESA use patterns, characteristics, and outcomes of ESA-treated/untreated patients were quantified...
June 11, 2018: BMC Nephrology
https://www.readbyqxmd.com/read/29779027/association-of-pre-end-stage-renal-disease-hemoglobin-with-early-dialysis-outcomes
#16
Carola-Ellen Kleine, Melissa Soohoo, Omesh N Ranasinghe, Christina Park, Maria V Marroquin, Yoshitsugu Obi, Connie M Rhee, Hamid Moradi, Csaba P Kovesdy, Kamyar Kalantar-Zadeh, Elani Streja
BACKGROUND: Incident hemodialysis patients have a high mortality risk within the first months after dialysis initiation. Pre-end-stage renal disease (ESRD) factors like anemia management may impact early post-ESRD outcomes. Therefore, we evaluated the impact of pre-ESRD hemoglobin (Hgb) and pre-ESRD Hgb slope on post-ESRD mortality and hospitalization outcomes. METHODS: The study included 31,472 veterans transitioning to ESRD. Using Cox and negative binomial regression models, we evaluated the association of pre-ESRD Hgb and Hgb slope with 12-month post-ESRD all-cause and cardiovascular mortality and hospitalization rates using 4 levels of hierarchical multivariable adjustment, including erythropoietin use and kidney decline in slope models...
2018: American Journal of Nephrology
https://www.readbyqxmd.com/read/29767854/emerging-association-between-parathyroid-hormone-and-anemia-in-hemodialysis-patients
#17
REVIEW
Motoko Tanaka, Hirotaka Komaba, Masafumi Fukagawa
Anemia is a common complication of chronic kidney disease (CKD). There are various causes of renal anemia such as decreased production of erythropoietin, resistance to erythropoietin, shortened survival of red blood cells, and bone marrow fibrosis. Secondary hyperparathyroidism (SHPT) is a less recognized, but potentially significant cause of renal anemia in CKD patients. Parathyroid hormone (PTH) has been regarded as a uremic toxin that has multiple adverse effects, and its elevated levels have been associated with renal anemia in hemodialysis patients...
June 2018: Therapeutic Apheresis and Dialysis
https://www.readbyqxmd.com/read/29744352/limitations-of-serum-ferritin-in-diagnosing-iron-deficiency-in-inflammatory-conditions
#18
REVIEW
Axel Dignass, Karima Farrag, Jürgen Stein
Patients with inflammatory conditions such as inflammatory bowel disease (IBD), chronic heart failure (CHF), and chronic kidney disease (CKD) have high rates of iron deficiency with adverse clinical consequences. Under normal circumstances, serum ferritin levels are a sensitive marker for iron status but ferritin is an acute-phase reactant that becomes elevated in response to inflammation, complicating the diagnosis. Proinflammatory cytokines also trigger an increase in hepcidin, which restricts uptake of dietary iron and promotes sequestration of iron by ferritin within storage sites...
2018: International Journal of Chronic Diseases
https://www.readbyqxmd.com/read/29734151/renal-anemia-and-iron-metabolism
#19
Chie Ogawa, Ken Tsuchiya, Kunimi Maeda, Kosaku Nitta
Normal iron metabolism is essential for effective hemoglobin (Hb) production in the management of renal anemia. Considering that studies regarding the optimal Hb levels predated the creation of the iron management indices found in the treatment guidelines for hemodialysis (HD) patients, an increase in the Hb levels caused by intravenous iron supplementation has been used as an iron management index. However, no consideration was given to iron metabolism or the long-term safety of intravenous iron supplementation...
2018: Contributions to Nephrology
https://www.readbyqxmd.com/read/29712435/prolyl-hydroxylase-inhibitors-a-breakthrough-in-the-therapy-of-anemia-associated-with-chronic-diseases
#20
Amit A Joharapurkar, Vrajesh B Pandya, Vishal J Patel, Ranjit C Desai, Mukul R Jain
Chronic kidney disease, cancer, chronic inflammatory disorders, nutritional, and genetic deficiency can cause anemia. Hypoxia causes induction of hypoxia-inducible factor (HIF), which stimulates erythropoietin (EPO) synthesis. Prolyl hydroxylase domain (PHD) enzyme inhibition can stabilize hypoxia-inducible factor (HIF). HIF stabilization also decreases hepcidin, a hormone of hepatic origin, which regulates iron homeostasis. PHD inhibitors represent a novel pharmacological treatment of anemia associated with chronic diseases...
May 9, 2018: Journal of Medicinal Chemistry
label_collection
label_collection
1756
1
2
2018-05-04 06:56:30
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"